PharmExec Direct eNewsletter

PharmExec Direct:
Having trouble viewing this e-mail? Click here.

You are subscribed to %%list.name%% as %%emailaddr%%.
Click here to unsubscribe or edit your member profile

PharmExec Direct | From the editors of Pharmaceutical Executive

August 26, 2010 | ISSUE NUMBER 163 VOL 8

Safety
Actos Deemed as Safe as Avandia
Results from a new study reveal that patients taking Takeda’s diabetes treatment Actos have the same rate and kind of side effects as GSK’s embattled Avandia. Is this a good sign?

Advertisement:
Capgemini
Are You Really Closing the Loop?
There is a considerable advantage to being one of the first companies in pharma to successfully close the loop and pave the way to a new commercial model that puts the customer first. However, implementing comprehensive, closed-loop marketing has proven difficult for many in our industry. Capgemini Consulting examines the functional implications for implementing closed-loop marketing across the commercial organization and the hurdles to overcome to fully close the loop. Click here

Sales
New Study Shows Spike in Branded Drug Prices
The AARP released its analysis of retail pricing trends for branded drugs, and the big reveal was that retail prices have spiked 8 percent in the past year.

Global
And What Exactly is a Stakeholder?
Pharma’s uncritical use of the word ‘stakeholder’ has increased to the point where it can refer to almost anyone connected to the industry. But this can have serious consequences, warns Reflector.

New & Noteworthy
Strategies for Emerging Markets: Seven Keys to the Kingdom
It’s back to the future in Pharm Exec’s second-annual review of industry prospects in the IMS “Pharmerging 17.”

// Jennerex appointed Lara Longpre chief operating officer. // PharMEDium elected William R. Spalding to its board of directors. // Regenicin appointed Amgen co-founder Joseph Rubinfeld to its board of directors. // Torbjorn Bjerke was named new CEO of Karolinska Development. // Kendle appointed Jeffrey M. Zucker to lead global patient recruitment efforts. // Matthew J. McCall joined Atlanta Clinical Care. //

Release Higher Performance Through Business Analytics
Wednesday, Sept. 22, 11 A.M. Eastern; 8 A.M. Pacific
Register Free at http://pharmexec.com/analytics

3-D Segmentation: Managing your Brand’s Three Most Important Influencers
Thursday, Oct. 7, at 12 P.M. Eastern; 9 A.M. Pacific
Register Free at http://pharmexec.com/geo

Sep 9–10 Clinical Trials in Latin America
Lima, Peru

Sep 29–30 6th Annual Bio/Pharmaceutical and Medical Device Product Recalls Summit
Washington, DC

Dec 8—9 CMAC 2010 - Commercialization and Market Access Congress
Orlando, FL

A year and a half into President Obama’s tenure, how do you view the effectiveness of the “new” FDA?

Journey to the Center of the Mind

J&J Plans to Improve Manufacturing Quality

Pharma Accused Of Misleading Regulators


	Follow Pharm Exec on Twitter
	Follow Pharm Exec on Facebook

You are subscribed to %%list.name%% as %%emailaddr%%. Click here to unsubscribe or edit your member profile.
To ensure delivery to your Inbox, please add us to your address book. If you need help doing this, click here.

Advanstar Communications provides certain customer contact data (such as customers' names, addresses, phone numbers and e-mail addresses) to third parties who wish to promote relevant products, services and other opportunities which may be of interest to you. If you do not want Advanstar Communications to make your contact information available to third parties for marketing purposes, simply call (toll free) 1-866-529-2922 at any time, or fax us at 1-218-740-6417. Outside the U.S., please phone 1-218-740-6395. Contact us by mail at Advanstar Communications Inc., 131 West First St., Duluth, MN 55802-2065, USA.